195. ヌーナン症候群 ［臨床試験数：10，薬物数：11（DrugBank：4），標的遺伝子数：2，標的パスウェイ数：9］
Searched query = "Noonan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03435627 | February 26, 2018 | 27 May 2019 | Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome) | Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome) | Genetic Disorder;Noonan Syndrome | Drug: Somatropin | Novo Nordisk A/S | Recruiting | 3 Years | N/A | All | 60 | N/A | Japan | |
| 2 | EUCTR2016-005022-10-DE | 13/02/2018 | 23 July 2018 | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Noonan Syndrom and Neurofibromatosis Type 1 MedDRA version: 20.0 Level: PT Classification code 10029748 Term: Noonan syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0 Level: PT Classification code 10029268 Term: Neurofibromatosis System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Not possible to specify | Product Name: Lovastatin Pharmaceutical Form: Capsule, hard INN or Proposed INN: Lovastatin CAS Number: 75330-75-5 Other descriptive name: LOVASTATIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Lamotrigin Pharmaceutical Form: Capsule, hard INN or Proposed INN: Lamotrigin CAS Number: 84057-84-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use | Technische Universität München Fakultät für Medizin | Authorised | Female: yes Male: yes | 28 | Phase 2 | Germany | |||
| 3 | NCT02713945 | January 25, 2017 | 22 July 2019 | Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome | Treatment With HMG-COA Reductase Inhibitor (Simvastatin) of Growth and Bone Abnormalities in Children With Noonan Syndrome: A Phase III Randomised, Double Blind, Placebo-controlled Therapeutic Trial | Noonan Syndrome | Drug: Simvastatin;Drug: Placebo | University Hospital, Toulouse | Recruiting | 6 Years | 16 Years | All | 62 | Phase 3 | France | |
| 4 | EUCTR2016-000647-14-FR | 23/05/2016 | 10 September 2018 | Treatment with simvastatin of growth and bone abnormalities in children with Noonan syndrome | Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in children with Noonan syndrome : a phase III randomised, double-blind, placebo-controlled therapeutic trial - RASTAT | Noonan syndrome;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] | Trade Name: Simvastatin Product Name: Simvastatin Pharmaceutical Form: Film-coated tablet Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | University Hospital Toulouse | Authorised | Female: yes Male: yes | 62 | Phase 3 | France | |||
| 5 | NCT01927861 | August 19, 2013 | 20 August 2018 | Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome | A 52-week, Multi-centre, Randomised, Double-blind, Parallel-group, no Treatment Controlled (Open-label) Trial Investigating the Efficacy and Safety of Two Doses of NN-220 in Short Stature With Noonan Syndrome | Genetic Disorder;Noonan Syndrome | Drug: somatropin | Novo Nordisk A/S | Not recruiting | 3 Years | 10 Years | All | 51 | Phase 3 | Japan | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2011-003392-10-GB | 23/01/2012 | 19 March 2012 | A study to look at the effect of the study drug on heart muscle thickness, the amount of drug that ends up in the blood, and the safety and tolerability of study drug in Noonan syndrome patients. | An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy. | Noonan syndrome hypertrophic cardiomyopathy MedDRA version: 14.1 Level: PT Classification code 10029748 Term: Noonan syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 14.1 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Code: MEK162 Pharmaceutical Form: Film-coated tablet CAS Number: 606143-89-9 Current Sponsor code: MEK162 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- | Novartis Pharma Services AG | Authorised | Female: yes Male: yes | 22 | United Kingdom;United States | ||||
| 7 | NCT01529944 | September 2008 | 19 February 2015 | Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658 | Genetic Testing of Noonan Subjects Previously Treated With Norditropin® in the GHNOO-1658 Trial | Genetic Disorder;Noonan Syndrome | Drug: somatropin | Novo Nordisk A/S | Not recruiting | N/A | N/A | Both | 22 | Phase 3 | Sweden | |
| 8 | NCT00351221 | May 2006 | 19 February 2015 | Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome | A Phase 2, Open-Label, Multicenter, Clinical Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 in Children With Growth Failure Due to Noonan Syndrome | Noonan Syndrome | Drug: rhIGF-1/rhIGFBP-3 | Insmed Incorporated | Not recruiting | 2 Years | 16 Years | Both | 24 | Phase 2 | United States | |
| 9 | EUCTR2005-000042-37-SE | 11/07/2005 | 19 March 2012 | Norditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit | Norditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit | Noonan syndrome associated short stature MedDRA version: 7.1 Level: PT Classification code 10029748 | Trade Name: Norditropin 24 IU Product Name: Norditropin 24 IU Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Somatropin Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 24- Trade Name: Norditropin SimpleXx Product Name: Norditropin SimpleXx Pharmaceutical Form: Solution for injection INN or Proposed INN: Somatropin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 3,3- INN or Proposed INN: Somatropin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6,7- INN or Proposed INN: Somatropin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- | Novo Nordisk A/S | Not Recruiting | Female: yes Male: yes | Sweden | |||||
| 10 | NCT00452725 | October 1997 | 19 February 2015 | Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome | Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome | Noonan Syndrome | Drug: MAXOMAT ®, biosynthetic growth hormone | Sanofi | Not recruiting | 3 Years | 15 Years | Both | 36 | Phase 3 | France |